Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | PI4KA | P42356 | 3/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841 | 0.85 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23513431 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922451 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL16526337 | 0.82 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.80 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11986907 | 0.78 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922453 | 0.78 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL233405 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL29387721 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4088282 | 0.77 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | ADORA2A 1309/4885ADORA1 2149/4885ADORA2B 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.